Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGIONASDAQ:GLPGNASDAQ:IRONNASDAQ:SIGA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$28.03-2.5%$28.94$23.42▼$62.58$1.62B0.77696,302 shs610,838 shsGLPGGalapagos$26.50-1.3%$25.39$22.36▼$31.23$1.75B0.02230,539 shs786,221 shsIRONDisc Medicine$45.73-1.3%$46.34$30.65▼$68.73$1.58B0.77349,566 shs218,935 shsSIGASIGA Technologies$5.93-0.2%$5.77$4.95▼$12.83$423.65M0.92740,457 shs554,292 shsFree Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals-2.47%-0.50%+1.85%-15.83%-17.90%GLPGGalapagos-1.27%+2.71%+9.50%+3.96%-7.44%IRONDisc Medicine-1.34%+5.01%+13.56%-15.47%+43.62%SIGASIGA Technologies-0.17%+12.95%-3.58%-1.98%-24.46%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGIOAgios Pharmaceuticals4.2224 of 5 stars3.31.00.04.24.00.81.9GLPGGalapagos0.49 of 5 stars0.83.00.00.03.30.00.6IRONDisc Medicine2.8754 of 5 stars4.51.00.00.03.02.50.0SIGASIGA Technologies1.824 of 5 stars0.01.00.00.03.40.83.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGIOAgios Pharmaceuticals 2.56Moderate Buy$56.0099.79% UpsideGLPGGalapagos 1.50Reduce$25.33-4.40% DownsideIRONDisc Medicine 3.09Buy$98.80116.05% UpsideSIGASIGA Technologies 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SIGA, AGIO, GLPG, and IRON Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2025IRONDisc MedicineBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$112.00 ➝ $120.005/2/2025AGIOAgios PharmaceuticalsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$74.00 ➝ $71.003/18/2025IRONDisc MedicineCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$99.00 ➝ $132.003/7/2025IRONDisc MedicineMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$85.003/3/2025IRONDisc MedicineScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$73.00 ➝ $75.002/27/2025IRONDisc MedicineTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy2/24/2025AGIOAgios PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$58.00 ➝ $58.00(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGIOAgios Pharmaceuticals$37.04M43.83N/AN/A$27.02 per share1.04GLPGGalapagos$288.19M6.06N/AN/A$47.57 per share0.56IRONDisc MedicineN/AN/AN/AN/A$14.17 per shareN/ASIGASIGA Technologies$138.72M3.05$0.94 per share6.34$2.77 per share2.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGIOAgios Pharmaceuticals$673.72M$11.242.47N/AN/A1,845.92%-2.51%-2.26%N/AGLPGGalapagos$80.16MN/A0.00N/AN/AN/AN/AN/A7/23/2025 (Estimated)IRONDisc Medicine-$76.43M-$3.92N/AN/AN/AN/A-25.24%-23.96%N/ASIGASIGA Technologies$68.07M$0.674.944.74N/A49.33%49.06%38.72%N/ALatest SIGA, AGIO, GLPG, and IRON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025SIGASIGA TechnologiesN/A-$0.01N/A-$0.01N/A$7.04 million5/7/2025Q1 2025IRONDisc Medicine-$0.99-$1.02-$0.03-$1.02N/AN/A5/1/2025Q1 2025AGIOAgios Pharmaceuticals-$1.80-$1.55+$0.25-$1.55$9.86 million$8.73 million4/23/2025Q1 2025GLPGGalapagos-$0.23-$2.47-$2.24-$2.45$72.22 million$97.33 million3/11/2025Q4 2024SIGASIGA TechnologiesN/A$0.63N/A$0.63N/A$81.40 million2/27/2025Q4 2024IRONDisc Medicine-$1.06-$0.98+$0.08-$0.98N/AN/A2/20/2025Q4 2024AGIOAgios Pharmaceuticals-$1.69-$1.74-$0.05-$1.74$9.35 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGIOAgios PharmaceuticalsN/AN/AN/AN/AN/AGLPGGalapagosN/AN/AN/AN/AN/AIRONDisc MedicineN/AN/AN/AN/AN/ASIGASIGA TechnologiesN/AN/AN/AN/AN/ALatest SIGA, AGIO, GLPG, and IRON DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/8/2025SIGASIGA Technologiesspecial$0.604/29/20254/29/20255/15/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGIOAgios PharmaceuticalsN/A11.9011.56GLPGGalapagosN/A9.979.81IRONDisc MedicineN/A19.3619.36SIGASIGA TechnologiesN/A8.105.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGIOAgios PharmaceuticalsN/AGLPGGalapagos32.46%IRONDisc Medicine83.70%SIGASIGA Technologies55.40%Insider OwnershipCompanyInsider OwnershipAGIOAgios Pharmaceuticals4.30%GLPGGalapagos2.91%IRONDisc Medicine4.24%SIGASIGA Technologies1.54%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGIOAgios Pharmaceuticals39057.92 million54.47 millionOptionableGLPGGalapagos1,31065.90 million63.98 millionOptionableIRONDisc Medicine3034.57 million28.50 millionNot OptionableSIGASIGA Technologies4071.44 million70.31 millionOptionableSIGA, AGIO, GLPG, and IRON HeadlinesRecent News About These CompaniesSIGA Technologies (NASDAQ:SIGA) Issues Quarterly Earnings ResultsMay 12 at 1:28 PM | marketbeat.comDimensional Fund Advisors LP Raises Stock Position in SIGA Technologies, Inc. (NASDAQ:SIGA)May 12 at 3:18 AM | marketbeat.comSIGA Technologies First Quarter 2025 Earnings: US$0.006 loss per share (vs US$0.14 profit in 1Q 2024)May 10, 2025 | finance.yahoo.comSIGA Technologies, Inc. (NASDAQ:SIGA) Q1 2025 Earnings Call TranscriptMay 9, 2025 | msn.comSIGA Reports Financial Results for Three Months Ended March 31, 2025May 8, 2025 | globenewswire.comInvestors Purchase Large Volume of SIGA Technologies Call Options (NASDAQ:SIGA)May 3, 2025 | marketbeat.comCalculating The Fair Value Of SIGA Technologies, Inc. (NASDAQ:SIGA)May 2, 2025 | finance.yahoo.comSiga Technologies Inc. (SIGA) Stock Declines While Market Improves: Some Information for InvestorsMay 1, 2025 | zacks.comSIGA to Host Business Update Call on May 8, 2025 Following Release of First-Quarter 2025 ResultsMay 1, 2025 | globenewswire.comChiliz joins SIGA to help drive integrity in sportApril 30, 2025 | en.as.comWhy SIGA Technologies, Inc.’s (SIGA) Stock Is Down 11.34%April 29, 2025 | aaii.comRenaissance Technologies LLC Acquires 293,836 Shares of SIGA Technologies, Inc. (NASDAQ:SIGA)April 28, 2025 | marketbeat.comHere's Why Siga Technologies Inc. (SIGA) Gained But Lagged the Market TodayApril 25, 2025 | zacks.comSiga Technologies Inc. (SIGA) Outperforms Broader Market: What You Need to KnowApril 23, 2025 | zacks.comSIGA Technologies Target of Unusually High Options Trading (NASDAQ:SIGA)April 19, 2025 | marketbeat.comSiga Technologies Inc. (SIGA) Stock Moves -1.82%: What You Should KnowApril 17, 2025 | msn.comLSV Asset Management Has $974,000 Stock Holdings in SIGA Technologies, Inc. (NASDAQ:SIGA)April 17, 2025 | marketbeat.com3 Stocks Upping Dividends & 1 With A 10% Special Dividend Yield (SIGA)April 16, 2025 | dividendstocks.comSiga Technologies Inc. (SIGA) Falls More Steeply Than Broader Market: What Investors Need to KnowApril 15, 2025 | zacks.comExodusPoint Capital Management LP Makes New Investment in SIGA Technologies, Inc. (NASDAQ:SIGA)April 15, 2025 | marketbeat.comSiga Technologies Shares Climb on Special DividendApril 8, 2025 | marketwatch.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSIGA, AGIO, GLPG, and IRON Company DescriptionsAgios Pharmaceuticals NASDAQ:AGIO$28.03 -0.71 (-2.47%) As of 05/14/2025 04:00 PM EasternAgios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Galapagos NASDAQ:GLPG$26.50 -0.34 (-1.27%) As of 05/14/2025 04:00 PM EasternGalapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.Disc Medicine NASDAQ:IRON$45.73 -0.62 (-1.34%) As of 05/14/2025 04:00 PM EasternDisc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.SIGA Technologies NASDAQ:SIGA$5.93 -0.01 (-0.17%) As of 05/14/2025 04:00 PM EasternSIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start AMD’s AI-Powered Stock Price Rally Just Shifted Gears Oklo Reaches Critical Mass, Atomic Upside Still Available Is Verizon a Buy? Q1 Results and Solid Dividend Make Bullish Case Carnival's Comeback: Is the Stock Set for a Profitable Journey? 5 Hot Small-Cap Insiders Bought at the Peak of Tariff Fears U.S. Regulators Target CrowdStrike: Is It a Signal or Noise? Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
